Alzheimer's Risks and Treatment

Health News

Losing your mind? Then, be MINDful: it could curb Alzheimer’s and dementia

A doctor explains the simple steps

Featured Health News photo

Don’t look now, but there’s another diet running wild, and this one may finally make some sense for seniors.

It’s called the “MIND” diet (what else?). “MIND” stands for “Mediterranean-DASH Intervention for Neurodegenerative Delay” and it was born out of research from Harvard’s School of Public Health and Rush University in Chicago. The “DASH” part stands for a separate diet – Dietary Approach to Stop Hypertension. If you followed all that, your mind is still working pret...

Read article
Featured Health News photo

Latest Articles

  1. CDC warns that this year's flu vaccine may not be as effective
  2. Unlicensed 'dental veneer techs' are putting people's health at risk
  3. Texas sues drug companies and pharmacy benefit managers over insulin prices
  4. Refunds being issued to LASIK customers
  5. Food allergy sufferers need more support, study finds

Not sure how to choose?

Get expert buying tips about Alzheimer's Risks and Treatment delivered to your inbox.

    By entering your email, you agree to sign up for consumer news, tips and giveaways from ConsumerAffairs. Unsubscribe at any time.

    Thanks for subscribing.

    You have successfully subscribed to our newsletter! Enjoy reading our tips and recommendations.

    Recent Articles

    Newest
    • Newest
    • Oldest
    Article Image

    Blood test to help diagnose Alzheimer's in testing stages

    Researchers are confident in the early results

    Testing for Alzheimer’s disease can be a long, costly, and tiresome process for patients, but researchers from Brigham and Women’s Hospital have been working to make the testing process easier on patients.

    The group has developed a blood test that would evaluate the level of tau -- the leading protein in the brain associated with Alzheimer’s -- before a patient is even showing signs or symptoms of the disease.

    “A blood test for Alzheimer’s disease could be administered easily and repeatedly, with patients going to their primary care office rather than having to go into a hospital,” said Dr. Dominic Walsh. “Ultimately, a blood-based test could replace cerebrospinal fluid testing and/or brain imaging. Our new test has the potential to do just that.”

    Though the test is currently in the testing stages, Dr. Walsh is calling it a “transformative breakthrough” based on the early results.

    How it works  

    Tau is a protein in the brain that is most typically associated with Alzheimer’s. Though tau can develop through a number of different related molecules, the researchers were able to create a model that differentiates between the individual types of tau to ensure that the blood test comes up with the most accurate result.

    The researchers have conducted two trials so far with participants from Harvard’s Aging Brain Study and the Institute of Neurology in London. The first group consisted of 65 participants and the second group had 86.

    Everyone involved in the study donated samples of plasma and cerebrospinal fluid, which helped the researchers look at the breakdown of the tau protein and see exactly what was linked to Alzheimer’s.

    In both tests, the researchers found one strand of tau -- NT1 -- that was effective in predicting and identifying cases of Alzheimer’s.

    The next step for the researchers is to open the test up to larger groups of participants to further test its effectiveness on a wider sample. However, these early results proved to Dr. Walsh and his team that they could be on the right track.

    “We’ve made our data and the tools needed to perform our test widely available because we want other research groups to put this to the test,” he said. “It’s important for others to validate our findings so that we can be certain this test will work across different populations.”

    Fighting Alzheimer’s

    While this blood test could potentially change the way doctors go about diagnosing Alzheimer’s, fellow researchers have made strides this year in an effort to better diagnose and treat the disease.

    In late September, researchers from the Clinical Memory Research Unit at Lund University in Sweden developed a new brain imaging technique that would help doctors make the most accurate Alzheimer’s diagnoses.

    The researchers used a PET scan to evaluate the level of tau in the brain by administering a marker for the protein before the test. The researchers found this new test to be more successful than traditional Alzheimer’s screening methods.

    “If the patient has tau in certain parts of the brain, the marker will detect it,” said researcher Oskar Hansson. “The result -- whether Alzheimer tau is present or not -- is very clearly visible on the PET images.”

    On the treatment front, researchers found success with a clinical trial for a drug being developed to treat Alzheimer’s.

    Amyloid is another protein often found in the brain with Alzheimer’s, and researchers from Biogen and Eisai worked to develop BAN2401 -- an anti-amyloid drug. Though unsuccessful in initial tests, this new and improved version of the drug was found to slow the progression of Alzheimer’s in the study’s clinical trial.

    Testing for Alzheimer’s disease can be a long, costly, and tiresome process for patients, but researchers from Brigham and Women’s Hospital have been worki...

    Article Image

    New study suggests a strong connection between herpes and Alzheimer's

    One researcher says herpes could account for '50 percent or more' of Alzheimer's cases

    While researchers continue to look for the cause of Alzheimer’s disease, a new study published in Frontiers in Aging Neuroscience explores the connection between the development of the condition and the herpes virus.

    Researcher Ruth Itzhaki has spent over two decades studying the relationship between herpes and Alzheimer’s, and in this most recent study she studied the effects that herpes flare ups have on neurons in the brain.

    Exploring the connection  

    Herpes never goes away entirely, with the condition often flaring up during times of stress or illness. The most severe form of herpes is Herpes Simplex Virus 1 (HSV1), and according to Itzhaki, this strand of the infection could account for “50 percent or more of Alzheimer’s disease cases.”

    A key component of Itzhaki’s theory was testing an antiviral drug that could alleviate the risk of senile dementia in people that had herpes.

    To get an accurate population sampling to test this theory, Itzhaki utilized data taken from Taiwan’s National Health Insurance Research Database, which documents information on disease and infections.

    As nearly all of Taiwan’s population is enrolled in the Database, Itzhaki was able to evaluate three studies published between 2017 and 2018 that described the ways patients with HSV1 were treated by healthcare professionals; the data showed the evolution of those with senile dementia.

    Itzhaki found that the antiviral drug was an effective course of treatment for those who were infected with HSV1 and then developed dementia. She also found that those who already have HSV1 areat a much greater risk of later developing senile dementia.

    Itzhaki noted that this study focuses on those with the most severe cases of the infection, and future research would have to focus on dementia rates in those with more mild forms of herpes.

    Despite this, Itzhaki was confident in the study’s results.

    “Considering that over 150 publications strongly support an HSV1 role in Alzheimer’s, these Taiwan findings greatly justify usage of anti-herpes antivirals -- which are safe and well tolerated -- to treat Alzheimer’s disease,” said Itzhaki. “They also incentivize development of an HSV1 vaccine, which would likely be the most effective treatment.”

    Recent Alzheimer’s breakthroughs

    Alzheimer’s research continues to be a point of emphasis for the medical community, and researchers have made considerable contributions to the field in recent months.

    Back in July, a major drug company reported positive results from a clinical trial for a new Alzheimer’s drug. The study involved nearly 900 participants in the early stages of Alzheimer’s, and after 18 months, the drug was found to be successful in slowing the progress of the disease.

    Later in the summer, researchers at the University of Adelaide found a link between iron in our cells and a rare genetic mutation that causes Alzheimer’s.

    Most recently, researchers from the Clinical Memory Research Unit at Lund University found a new brain imaging technique that would help doctors diagnose Alzheimer’s more accurately. The PET scan involved in the study proved to be more successful than traditional treatments that are currently used to diagnose Alzheimer’s, and the researchers are confident the method will gain popularity worldwide.

    While researchers continue to look for the cause of Alzheimer’s disease, a new study published in Frontiers in Aging Neuroscience explores the connection b...